anthydoc – Page 234

STAT+: Startup Altido Therapeutics pursues CAR-T for glioblastoma tumors

Nick Leschly, the CEO who became synonymous with the curative promise and complicated reality of gene therapy, is back with a new company. The startup, Altido Therapeutics, is trying to commercialize a

January 28, 2026

Opinion

From the community | MAHA is worsening nutrition insecurity — ‘Food is Medicine’ can do better

Med School Ph.D. argues that cutting SNAP/WIC benefits worsens nutrition insecurity, and that investment into culturally-appropriate solutions is necessary.

January 28, 2026

Supplement

Cellares’ series D round draws $257M as cell therapy contractor takes operations global

With Cellares preparing to begin commercial-stage production in 2027, the California-based cell therapy contract manufacturer has taken a major step toward that goal, raising $257 million in a series D round.

January 28, 2026

News·Solutions

Antheia seals 2nd series C funding close, hitting more than $175M in a year

Biosynthesis specialist Antheia has topped off its series C funding with a second close, adding $24 million more to its haul. The financing lift brings Antheia’s total funding over the past year

January 28, 2026

News·Solutions

NotCo: How AI can help companies align innovation with new US dietary guidelines

The 2025–2030 Dietary Guidelines for Americans are prompting food and nutrition companies to rethink their innovation strategies, focusing on reduced sugar, sodium, and saturated fats and increased high-quality protein and fiber.Nutrition Insight

January 28, 2026

Supplement

KENT Nutrition’s ARGIS wins IPPE ‘Best of the Best’ award

Innovative probiotic recognized for advancing poultry and swine nutrition at IPPE 2026

January 28, 2026

Supplement

Is Abbott (ABT) Insider Buying Offsetting Concerns Around Nutrition and Diagnostics Earnings Pressure?

Abbott Laboratories reported fourth-quarter 2025 sales of US$11,459 million, with net income dropping to US$1,776 million and diluted EPS from continuing operations at US$1.01, compared with the prior year. The earnings shortfall

January 28, 2026

Supplement